Hipskind
John Hipskind, Research Triangle Park, NC US
Patent application number | Description | Published |
---|---|---|
20100017918 | ARABIDOPSIS DERIVED PROMOTERS FOR REGULATION OF PLANT EXPRESSION - The invention provides a method to identify a plurality of plant promoters having specified characteristics and promoters identified by the method. Also provided are transgenic plants comprising the genes identified by the methods of the invention. | 01-21-2010 |
John Hipskind, Durham, NC US
Patent application number | Description | Published |
---|---|---|
20090205075 | USE OF PLASTID TRANSIT PEPTIDES DERIVED FROM GLAUCOCYSTOPHYTES - Compositions and methods for targeting polypeptides to plastids are provided. Compositions comprise plastid transit peptides as well as nucleotide sequences encoding such transit peptides and variants thereof. Compositions further comprise DNA constructs comprising a nucleotide sequence encoding the plastid transit peptide operably linked to a nucleotide sequence encoding a polypeptide of interest. These DNA constructs find use in expression and targeting of the polypeptide of interest to a plastid. Compositions also comprise expression cassettes, vectors, transformed plants, transformed plant cells, and stably transformed plant seeds wherein a polypeptide of interest is targeted to a plastid by the plastid transit peptide of the invention. | 08-13-2009 |
20120284878 | ARABIDOPSIS DERIVED PROMOTERS FOR REGULATION OF PLANT EXPRESSION - The invention provides a method to identify a plurality of plant promoters having specified characteristics and promoters identified by the method. Also provided are transgenic plants comprising the genes identified by the methods of the invention. | 11-08-2012 |
20120284881 | ARABIDOPSIS DERIVED PROMOTERS FOR REGULATION OF PLANT EXPRESSION - The invention provides a method to identify a plurality of plant promoters having specified characteristics and promoters identified by the method. Also provided are transgenic plants comprising the genes identified by the methods of the invention. | 11-08-2012 |
John Daniel Hipskind, Durham, NC US
Patent application number | Description | Published |
---|---|---|
20120324600 | CONSTITUTIVE SYNTHETIC PLANT PROMOTERS AND METHODS OF USE - Control of transgene expression in planta is dependent upon genetic elements that affect both transcription and translation of mRNA transcripts. The disclosed invention describes the combination of DNA elements from four different plant viruses that function as an activator of transcription and enhancer of translation of mRNA transcripts in transgenic plants. | 12-20-2012 |
20140201860 | SOYBEAN EVENT SYHT0H2 AND COMPOSITIONS AND METHODS FOR DETECTION THEREOF - Soybean plants comprising event SYHT0H2, methods of detecting and using the same, and soybean plants comprising a heterologous insert at the same site as SYHT0H2. | 07-17-2014 |
20140310835 | SOYBEAN EVENT SYHT04R AND COMPOSITIONS AND METHODS FOR DETECTION THEREOF - Soybean plants comprising event SYHT04R, methods of detecting and using the same, and soybean plants comprising a heterologous insert at the same site as SYHT04R. | 10-16-2014 |
John Daniel Hipskind, Research Triangle Park, NC US
Patent application number | Description | Published |
---|---|---|
20140259222 | PATHOGEN RESISTANCE - Disease in food crops caused by fungal pathogens is a major concern to the agricultural industry, with annual losses typically in the billions of dollars. | 09-11-2014 |
Kelly T. Hipskind, Carmel, IN US
Patent application number | Description | Published |
---|---|---|
20130302767 | INTERACTIVE KISOKS SYSTEM AND METHOD FOR REWARDS BASED EDUCATION - A computer implemented student attendance tracking and award credit accumulation system in which class and school attendance data associated with a student is tracked, recorded and reported to select parties in real-time. In the computer implemented system and method, a student earns award credits for class and school attendance, in real-time, and the system immediately updates an accumulation balance of student award credits stored within data storage at a web based interface server. The system includes a plurality of data input terminals and a web based interface server, wherein the input terminals may comprise kiosks, desktop workstations and/or laptops. Each data input terminal includes a student identification retrieval device and is configured for retrieving student identification data for input into the web based interface server. The student identification retrieval device may comprise a card swipe communication system or an RFID receiver for receiving student identification data from identification data transmitted from an RFID identifier attached and stored on a student identification card. | 11-14-2013 |
Kelly T. Hipskind, Indianapolis, IN US
Patent application number | Description | Published |
---|---|---|
20110173549 | INTERACTIVE KIOSK SYSTEM AND METHOD - Provided is an interactive kiosk system and method of use. Certain embodiments of a kiosk system may provide users with a wide variety of targeted information, materials and/or services that can be separately administered remotely by multiple unique parties, such as, for example, a plurality of advertisers and one or more managers. In certain embodiments, an interactive kiosk may include videoconferencing capability so that a manager can provide virtual face-to-face assistance to a user. In certain embodiments, an interactive kiosk provides a uniform interface adapted to allow the user to interact with the reservation systems of a plurality of third-parties when the user's identification or payment information is entered only once. | 07-14-2011 |
Philip A. Hipskind, Indianapolis, IN US
Patent application number | Description | Published |
---|---|---|
20150105367 | RAF INHIBITOR COMPOUNDS - This invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I); and use of a compound of Formula (I) for treating specified cancers. | 04-16-2015 |
Philip Arthur Hipskind, Palestine, IN US
Patent application number | Description | Published |
---|---|---|
20100022560 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS - The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and the use of such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome. | 01-28-2010 |
20100222339 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists - The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome. | 09-02-2010 |
Philip Arthur Hipskind, New Palastine, IN US
Patent application number | Description | Published |
---|---|---|
20100324048 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS - The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer. | 12-23-2010 |
20120316174 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS - The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer. | 12-13-2012 |
Robert Hipskind, Saint Gely Du Fesc FR
Patent application number | Description | Published |
---|---|---|
20110150936 | ANTI-TUMORAL CELLS - The present invention relates to the field of preventive or therapeutic anti-tumoral vaccine. More specifically, the present invention relates to live animal tumour cells having a negative MHC-I phenotype, to methods for the production of such MHC-I negative cells, and to their therapeutic use as anti-tumoral agents, particularly via their capacity to activate natural killer (NK) cells. The invention further relates to methods for modulating the level of expression of MHC-I molecules on animal tumour cells, for example by use of specific culture conditions, and/or by use of exogenous agents which directly or indirectly affect levels of MHC-I expression. The invention also concerns activated NK cells and their therapeutic use as anti-tumoral agents. | 06-23-2011 |